AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03200587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
Study NCT01720615 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Propofol / Remifentanil
Description: General anesthesia: Loss of consciousness and standard clinical practice
Study NCT00730951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Starch
Description: 500mg Capsulated Corn Starch
Study NCT03042520 — intervention group
Intervention type: OTHER
Intervention: Observation only
Study NCT01552018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: Saxagliptin 5 mg, 1 tablet per day for 3 months
Study NCT01552018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 tablet per day for 3 months.
Study NCT04582344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac
Description: Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
Study NCT04582344 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
Study NCT00669461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone 24 mcg BID orally for 4 weeks
Study NCT00959920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling catheter
Description: Indwelling bladder catheter will remain in place until time of delivery.
Study NCT00959920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent straight catheterization
Description: intermittent straight catheterization will be performed on an as needed basis until time of delivery.
Study NCT05013606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen water
Description: This is an over the counter pill supplement that is dissolved in water.
Study NCT05013606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen water
Description: This is an over the counter pill supplement that is dissolved in water.
Study NCT01906060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q Intubation Laryngeal Mask
Description: Patients will be intubated using the Air-Q Laryngeal Mask.
Study NCT00707590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-767778 or Placebo
Study NCT00105794 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Psychiatric Advance Directives intervention
Study NCT05351372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-low dose protocol
Study NCT05351372 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose protocol
Study NCT02485041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg
Description: Tablet, Orally administered
Study NCT02485041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100mg
Description: Table, Orally administered
Study NCT02220491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy
Description: Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
Study NCT02220491 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-brain radiotherapy
Description: Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
Study NCT02700867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIO
Description: Intraosseous access device NIO (Defibtech)
Study NCT02215044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536, intravenous
Study NCT02215044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, intravenous
Study NCT04658849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 Mg Oral Tablet
Description: Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily.
Study NCT04658849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone placebo tablet
Description: Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
Study NCT03874156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
Study NCT03874156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
Study NCT04409210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Establishment of individual health records
Description: Patients could upload self-test data (such as blood pressure, blood glucose, heart rate and weight) and medical institution examination data (such as blood lipids, ECG, echocardiography, etc.) through App. AND then the App can automatically generate health reports to reflect the dynamic changes of the data in the form of charts and whether the data is normal or not. It is convenient for patients to have a clear understanding of their health management, and if there are outliers, they can intervene in time.
Study NCT04409210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk assessment
Description: The China-PAR risk prediction tool can be used to stratify the 10-years atherosclerotic cardiovascular disease (ASCVD) risk. Those with predicted risks of \<5%, 5-10%, and ≥10% could be classified into categories of low-, moderate-, and high-risk for ASCVD, respectively. It is a risk prediction tool for Chinese developed by the team of Professor Gu Dongfeng of Fuwai Hospital of the Chinese Academy of Medical Sciences. When patients are aware of their risk of cardio-cerebrovascular diseases, it is helpful for patients to take the initiative to manage their cardio-cerebrovascular health.
Study NCT04409210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Popularization of medical knowledge
Description: Health education is divided into nine modules, such as introduction of cardio-cerebrovascular diseases, diet, exercise, sleep, psychology, medicine, cardiopulmonary resuscitation and cardiac self-rescue technology. The presentation of health education includes three modules: text, video and voice. Video and voice modules are more suitable for illiterates or people are inconvenient to read text. It mainly takes into account the fact that most of the high-risk population of cardio-cerebrovascular diseases are the elderly.
Study NCT04409210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Reminders
Description: 1. Abnormal data reminder App can automatically judge whether the data is normal. If abnormal data is found, it will inform the patient in red font and remind the patient to consult the doctor in time. Patients can consult their family doctors directly online through App or go to the hospital.~2. Medication reminder After patients upload their own medication information, the App will automatically generate a medication alarm clock to remind patients to take the drugs.~3. Follow-up reminder According to the clinical diagnosis and conditions of patients, make personalized follow-up time. Family physicians could use the App to remind patients to fill in the follow-up form or go to the hospital.
Study NCT04409210 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Routine treatment
Description: Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
Study NCT04409210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
Study NCT00908947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA followed by placement of LifeStent® Vascular Stent
Description: PTA followed by placement of LifeStent® Vascular Stent
Study NCT00169780 — intervention group
Intervention type: RADIATION
Intervention: High definition helical CT (64 head scanner)
Description: Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs.
Study NCT04475224 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KP-100IT
Description: Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
Study NCT02138331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC exosomes.
Description: Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
Study NCT04346524 — intervention group
Intervention type: OTHER
Intervention: sampling of microbiome
Description: women will sample from vagina, feces, and saliva during pregnancy
Study NCT01141933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-existential intervention
Description: Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
Study NCT01141933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: This group receive the usual treatment only.
Study NCT01764451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT04594330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: virgin coconut oil (VCO)
Description: 15 mL of VCO twice a day for 14 days
Study NCT04594330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 15 mL of placebo twice a day for 14 days
Study NCT00504114 — intervention group
Intervention type: PROCEDURE
Intervention: ACL Reconstruction Surgery
Study NCT00504114 — intervention group
Intervention type: PROCEDURE
Intervention: Cartilage Resurfacing Surgery
Study NCT00504114 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Replacement
Study NCT01092806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
Study NCT01092806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
Study NCT04459988 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: Description Needed
Study NCT03441360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Intravenous infusion
Study NCT00753168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-730 ophthalmic solution
Description: one eye drop twice daily
Study NCT00753168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol maleate ophthalmic solution
Description: one eye drop twice daily
Study NCT00753168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OT-730 placebo
Description: one eye drop twice daily
Study NCT03639324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose combination 1-1
Description: 100 mg QD of idelalisib + 100 mg QD of venetoclax
Study NCT03639324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose combination 1-2
Description: 100 mg QD of idelalisib + 200 mg QD of venetoclax
Study NCT03639324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose combination 1-3
Description: 100 mg BID of idelalisib + 200 mg QD of venetoclax
Study NCT03639324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose combination 1-4
Description: 150 mg BID of idelalisib + 200 mg QD of venetoclax
Study NCT03639324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-Trial: Dose combination 2-1
Description: 100 mg BID of idelalisib + 100 mg QD of venetoclax
Study NCT01720615 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Sevoflurane / Remifentanil
Description: General anesthesia: Loss of consciousness and standard clinical practice
Study NCT03387904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Irinotecan
Description: Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
Study NCT00661921 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 108
Description: IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
Study NCT03387904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan Day 1,8 ivgtt
Study NCT01746732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Oral administration
Study NCT01746732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Oral administration
Study NCT00661921 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AMG 108 volume matching placebo
Study NCT00891423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem short infusion
Study NCT00891423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem extended infusion
Study NCT03979833 — intervention group
Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
Study NCT02589886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and self-help internet intervention
Description: The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
Study NCT02146976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: introvenious infusion of propofol
Study NCT02146976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
Study NCT02306837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu-CY-E
Description: mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
Study NCT00004079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SarCNU
Description: Given PO
Study NCT00004079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00004079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03054831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liquid oxycodone
Description: The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).~In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
Study NCT02235584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone are given dexamethasone tablets of 2mg twice daily.
Study NCT01556282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
Study NCT04526652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Evaluating anxiety score in both arms
Study NCT04526652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Evaluating anxiety score in both arms
Study NCT02408445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone cypionate 200mg/ml
Description: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
Study NCT02582788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bathing Additive
Study NCT01182662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived MSCs and cyclosporin A
Description: 1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
Study NCT01182662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A
Description: cyclosporin A 5mg/kg po for 12 months
Study NCT02577224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-initiated treatment
Description: Please see Intervention Arm
Study NCT00991510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (Myfenax)
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Study NCT00991510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (Cellcept)
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Study NCT03345264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online, interactive self-help program
Description: Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
Study NCT01592721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR Antisense DNA
Description: EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
Study NCT01197768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
Study NCT01079819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 50 mg, once daily, 1 Day
Study NCT01079819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, once daily, 14 Days
Study NCT01079819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0 mg, One daily, 1 Day
Study NCT01079819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0 mg, One daily, 14 Day